References of "DELANAYE, Pierre"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailThe global burden of chronic kidney disease: estimates, variability and pitfalls.
Glassock, RJ; Warnock, DG; DELANAYE, Pierre ULg

in Nature Reviews Nephrology (2017), 13(2), 104-114

Detailed reference viewed: 19 (0 ULg)
Full Text
Peer Reviewed
See detailAssociation entre taux circulants de matrix-gla protéine et rigidité artérielle en transplantation rénale.
Dinic, Miriana; Maillard, Nicolas; DELANAYE, Pierre ULg et al

Conference (2016, December)

Detailed reference viewed: 20 (6 ULg)
See detailThe closure of arteriovenous fistula is associated with a significant acceleration of eGFR decline in kidney transplant recipients
Jouret, François ULg; DELANAYE, Pierre ULg; VANDERWECKENE, Pauline ULg et al

Poster (2016, November)

Background The creation of arteriovenous fistula (AVF) may retard chronic kidney disease progression in the general population. Conversely, there is limited literature regarding the impact of AVF closure ... [more ▼]

Background The creation of arteriovenous fistula (AVF) may retard chronic kidney disease progression in the general population. Conversely, there is limited literature regarding the impact of AVF closure on renal function in kidney transplant recipients (KTR). Methods All KTR were retrospectively identified from 01/01/2007 to 31/12/2013, and grouped into: (0) no AVF; (1) closed AVF; and (2) left open AVF. Glomerular filtration rate was estimated (eGFR) upon MDRD and FAS equations. Linear mixed models calculated the slope and intercept of eGFR decline versus time, starting at 3 months post transplantation (Tx). Comparative analyses of eGFR slopes were performed among groups, as well as before vs after AVF closure in group 1. For the latter, time was balanced before vs after AVF closure, with at least 10 observations per patient. Results The cohort included 285 KTR (Table 1), with a median follow-up of 1750 days [1665; 2028]. Focusing on group 1, AVF closure occurred after a mean time of 653 ± 441 days post Tx, with a thrombosis/ligation ratio of 19/95. Balanced study periods before vs after AVF closure lasted 15.7 and 14.9 months, respectively. No difference was found between corresponding intercepts (p, 0.11). By contrast, eGFR slopes were significantly different before (0.043 ml/min/year) versus after (-0.176 ml/min/year) AVF closure (p, 0.0115). Similar observations were obtained using FAS equation Conclusion A significant acceleration of eGFR decline is observed over the 15 months following the closure of functioning AVF in KTR. [less ▲]

Detailed reference viewed: 45 (4 ULg)
Full Text
Peer Reviewed
See detailComparisons of estimated GFR and Cockcroft Gault equations: calibration against relative risk for all-cause mortality.
Warnock, DG; van den Brand, JAJG; DELANAYE, Pierre ULg et al

Poster (2016, November)

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailGlomerular filtration rate in healthy living potential kidney donors: a meta-analysis.
Pottel, H; Hoste; DELANAYE, Pierre ULg

Poster (2016, November)

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailWeak performance of glomerular filtration rate equations in stable lung/liver transplant recipients compared to 51Cr-EDTA clearance.
Navaux, Emilie; Gustot, Thierry; Racape, Judith et al

Conference (2016, November)

Detailed reference viewed: 11 (2 ULg)
Full Text
See detailIs there a place for BTR markers in renal osteodystrophy?
DELANAYE, Pierre ULg

Conference (2016, October 15)

Detailed reference viewed: 23 (1 ULg)
Full Text
See detailHow to measure renal function?
DELANAYE, Pierre ULg

Conference (2016, October 14)

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailIohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1 : How to measure glomerular filtration rate with iohexol?
DELANAYE, Pierre ULg; Ebert, Natalie; Melsom, Toralf et al

in Clinical Kidney Journal (2016)

While there is general agreement on the necessity tomeasure glomerular filtration rate (GFR) inmany clinical situations, there is less agreement on the bestmethod to achieve this purpose. As the gold ... [more ▼]

While there is general agreement on the necessity tomeasure glomerular filtration rate (GFR) inmany clinical situations, there is less agreement on the bestmethod to achieve this purpose. As the gold standardmethod for GFR determination, urinary (or renal) clearance of inulin, fades into the background due to inconvenience and high cost, a diversity of filtrationmarkers and protocols compete to replace it. In this review, we suggest that iohexol, a non-ionic contrast agent, is most suited to replace inulin as the marker of choice for GFR determination. Iohexol comes very close to fulfilling all requirements for an ideal GFRmarker in terms of low extra-renal excretion, low protein binding and in being neither secreted nor reabsorbed by the kidney. In addition, iohexol is virtually non-toxic and carries a low cost. As iohexol is stable in plasma, administration and sample analysis can be separated in both space and time, allowing access to GFR determination across different settings. An external proficiency programme operated by Equalis AB, Sweden, exists for iohexol, facilitating interlaboratory comparison of results. Plasma clearance measurement is the protocol of choice as it combines a reliable GFR determination with convenience for the patient. Single-sample protocols dominate, butmultiple-sample protocolsmay bemore accurate in specific situations. In lowGFRs one ormore late samples should be included to improve accuracy. In patients with large oedema or ascites, urinary clearance protocols should be employed. In conclusion, plasma clearance of iohexol may well be the best candidate for a common GFR determination method. [less ▲]

Detailed reference viewed: 29 (7 ULg)
Full Text
Peer Reviewed
See detailIohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?
DELANAYE, Pierre ULg; Melson, Toralf; Ebert, Natalie et al

in Clinical Kidney Journal (2016)

2 | P. Delanaye et al. Abstract A reliable assessment of glomerular filtration rate (GFR) is of paramount importance in clinical practice as well as epidemiological and clinical research settings. It is ... [more ▼]

2 | P. Delanaye et al. Abstract A reliable assessment of glomerular filtration rate (GFR) is of paramount importance in clinical practice as well as epidemiological and clinical research settings. It is recommended by Kidney Disease: Improving Global Outcomes guidelines in specific populations (anorectic, cirrhotic, obese, renal and non-renal transplant patients) where estimation equations are unreliable. Measured GFR is the only valuable test to confirm or confute the status of chronic kidney disease (CKD), to evaluate the slope of renal function decay over time, to assess the suitability of living kidney donors and for dosing of potentially toxic medication with a narrowtherapeutic index. Abnormally elevatedGFRor hyperfiltration in patients with diabetes or obesity can be correctly diagnosed only by measuring GFR. GFR measurement contributes to assessing the true CKD prevalence rate, avoiding discrepancies duetoGFRestimation with different equations. Usingmeasured GFR, successfullyaccomplished in large epidemiological studies, is the onlyway to study the potential link between decreased renal functionand cardiovascular or total mortality, being sure that this association is not due to confounders, i.e. non-GFR determinants of biomarkers. In clinical research, it has been shown that measured GFR (or measured GFR slope) as a secondary endpoint as compared with estimated GFR detected subtle treatment effects and obtained these results with a comparatively smaller sample size than trials choosing estimated GFR. Measuring GFR by iohexol has several advantages: simplicity, low cost, stability and low interlaboratory variation. Iohexol plasma clearance represents the best chance for implementing a standardized GFR measurement protocol applicable worldwide both in clinical practice and in research. [less ▲]

Detailed reference viewed: 15 (3 ULg)
Full Text
Peer Reviewed
See detailValeurs de référence de débit de filtration glomérulaire en population noire-africaine
Yayo, E; Monnet, D; Attoungbré, M.-L. et al

in Néphrologie & Thérapeutique (2016, September), 12(5), 273

Detailed reference viewed: 25 (2 ULg)
Full Text
Peer Reviewed
See detailThe role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club.
Cavalier, Etienne ULg; Bergmann, P.; Bruyère, Olivier ULg et al

in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2016), 27

The exact role of biochemical markers of bone turnover in the management of metabolic bone diseases remains a topic of controversy. In this consensus paper, the Belgian Bone Club aimed to provide a state ... [more ▼]

The exact role of biochemical markers of bone turnover in the management of metabolic bone diseases remains a topic of controversy. In this consensus paper, the Belgian Bone Club aimed to provide a state of the art on the use of these biomarkers in different clinical or physiological situations like in postmenopausal women, osteoporosis in men, in elderly patients, in patients suffering from bone metastasis, in patients with chronic renal failure, in pregnant or lactating women, in intensive care patients, and in diabetics. We also gave our considerations on the analytical issues linked to the use of these biomarkers, on potential new emerging biomarkers, and on the use of bone turnover biomarkers in the follow-up of patients treated with new drugs for osteoporosis. [less ▲]

Detailed reference viewed: 38 (7 ULg)
Full Text
Peer Reviewed
See detailKidney-Failure Risk Projection for the Living Kidney-Donor candidate.
DELANAYE, Pierre ULg; Glassock, Richard

in New England Journal of Medicine (2016), 374(21), 2093-2094

Detailed reference viewed: 25 (3 ULg)